WO1993020099A3 - Ligands pour les recepteurs de la cck et/ou la gastrine - Google Patents

Ligands pour les recepteurs de la cck et/ou la gastrine Download PDF

Info

Publication number
WO1993020099A3
WO1993020099A3 PCT/GB1993/000614 GB9300614W WO9320099A3 WO 1993020099 A3 WO1993020099 A3 WO 1993020099A3 GB 9300614 W GB9300614 W GB 9300614W WO 9320099 A3 WO9320099 A3 WO 9320099A3
Authority
WO
WIPO (PCT)
Prior art keywords
cck
compounds
treatment
receptor ligands
medicinal compositions
Prior art date
Application number
PCT/GB1993/000614
Other languages
English (en)
Other versions
WO1993020099A2 (fr
Inventor
Hamish Ryder
David Alan Kendrick
Graeme Semple
Keiji Miyata
Andrzej Roman Batt
Elizabeth Alice Mathews
David Philip Rooker
Akito Nishida
Original Assignee
Ferring Bv
Yamanouchi Pharma Co Ltd
Hamish Ryder
David Alan Kendrick
Graeme Semple
Keiji Miyata
Andrzej Roman Batt
Elizabeth Alice Mathews
David Philip Rooker
Akito Nishida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv, Yamanouchi Pharma Co Ltd, Hamish Ryder, David Alan Kendrick, Graeme Semple, Keiji Miyata, Andrzej Roman Batt, Elizabeth Alice Mathews, David Philip Rooker, Akito Nishida filed Critical Ferring Bv
Publication of WO1993020099A2 publication Critical patent/WO1993020099A2/fr
Publication of WO1993020099A3 publication Critical patent/WO1993020099A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux composés de la structure générale A-B-C et leurs sels acceptables sur le plan pharmaceutique, des compositions médicinales les contenant et l'utilisation de telles compositions médicinales pour le traitement de certaines maladies. Les composés de l'invention sont représentés schématiquement par A-B-C où S1-S4 sont d'une façon générale des groupements lipophiles, S5 est un groupement polaire ou hydrophile et L1-L5 sont des unités de liaison facultatives. Les composés de cette invention se fixent aux récepteurs de la cholécystokinine et/ou de la gastrine avec une très grande affinité et sont donc utiles pour le traitement de maladies découlant d'un dysfonctionnement d'un processus physiologique régulé par l'une ou l'autre de ces hormones.
PCT/GB1993/000614 1992-03-27 1993-03-25 Ligands pour les recepteurs de la cck et/ou la gastrine WO1993020099A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9206757.8 1992-03-27
GB929206757A GB9206757D0 (en) 1992-03-27 1992-03-27 Novel peptide receptor ligands

Publications (2)

Publication Number Publication Date
WO1993020099A2 WO1993020099A2 (fr) 1993-10-14
WO1993020099A3 true WO1993020099A3 (fr) 1993-11-25

Family

ID=10712996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000614 WO1993020099A2 (fr) 1992-03-27 1993-03-25 Ligands pour les recepteurs de la cck et/ou la gastrine

Country Status (3)

Country Link
AU (1) AU3764593A (fr)
GB (1) GB9206757D0 (fr)
WO (1) WO1993020099A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922428A (zh) * 2015-06-25 2018-04-17 普洛麦格公司 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152989T3 (es) * 1993-08-10 2001-02-16 Black James Foundation Ligandos para los receptores de gastrina y cck.
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
CA2342471C (fr) * 1995-06-06 2002-10-29 Judith L. Treadway Intermediaires amines de carbonyle-methyle heterocycliques
AP624A (en) 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
KR100241643B1 (ko) 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
GB9610974D0 (en) * 1996-05-24 1996-07-31 Zeneca Ltd Herbicides
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
DK1042288T3 (da) * 1997-12-23 2008-01-28 Inst Nat Sante Rech Med Tripeptidyl-peptidase inhibitorer
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
WO1999062514A1 (fr) * 1998-06-03 1999-12-09 Cortech Inc. Indole et tetrahydroisoquinoleine contenant des alpha-ceto oxadiazoles comme inhibiteurs de serines-proteases
EP1114822A3 (fr) * 1998-06-03 2002-11-13 Cortech Inc. Indoles et tétrahydroisoquinolines contenant des alpha-céto-oxadiazoles comme inhibiteurs de sérine-protéases
OA11663A (en) 1998-10-08 2004-12-08 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors recptors (antipsychotic agents).
WO2000035453A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035452A1 (fr) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
CA2347912A1 (fr) 1998-12-18 2000-06-22 Soo S. Ko Piperidines heterocycliques utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6897234B2 (en) 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SE0000382D0 (sv) 2000-02-07 2000-02-07 Astrazeneca Ab New process
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2004517805A (ja) 2000-06-30 2004-06-17 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのｎ−ウレイドヘテロシクロアルキル−ピペリジン
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
WO2003041641A2 (fr) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Analogues de tetrahydroisoquinoline utiles comme modulateurs de l'activite du recepteur des chimiokines
DE60312516T2 (de) 2002-06-14 2007-11-22 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
ATE446094T1 (de) 2002-06-14 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
WO2005018547A2 (fr) 2003-08-15 2005-03-03 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
JP4773961B2 (ja) 2003-08-15 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害薬
AU2004264533B2 (en) 2003-08-15 2009-01-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
FR2876102A1 (fr) * 2004-10-04 2006-04-07 Solvay Compose heterocyclique enantiopur
JP5121346B2 (ja) * 2007-08-07 2013-01-16 国立大学法人 長崎大学 光学活性プロリンエステル誘導体およびｎ−ホルミル光学活性プロリン誘導体の製造方法
AU2010332765C1 (en) 2009-12-18 2016-09-29 Epics Therapeutics Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of G-Protein Coupled Receptor 43 (GPR43)
PE20140471A1 (es) 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos
EP2766346B1 (fr) 2011-10-14 2017-03-29 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués comme inhibiteurs du facteur xia
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
WO2013055984A1 (fr) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés tétrahydroisoquinolines substitués en tant qu'inhibiteurs du facteur xia
CN105121429B (zh) 2012-06-28 2017-12-12 诺华股份有限公司 补体途径调节剂和其用途
WO2014002058A2 (fr) 2012-06-28 2014-01-03 Novartis Ag Modulateurs de la voie du complément et utilisations de ceux-ci
CN104619698B (zh) 2012-06-28 2016-08-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
IN2015DN00185A (fr) 2012-07-12 2015-06-12 Novartis Ag
WO2014059202A1 (fr) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués par guanidine comme inhibiteurs du facteur xia
KR102143257B1 (ko) 2012-10-12 2020-08-10 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제의 결정질 형태
EP2906541B1 (fr) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Composés de tetrahydroisoquinoline substitués par guanidine et amine en tant qu'inhibiteurs de factor xia
EP2978751B1 (fr) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia
MX2016006975A (es) 2013-11-27 2016-10-12 Euroscreen Sa Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (fr) 2014-01-31 2018-03-10
MX2016011038A (es) 2014-02-25 2017-05-12 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos mediados por complemento.
WO2016036893A1 (fr) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamides macrocycliques qui sont des inhibiteurs de fxia
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
WO2017035361A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés disubstitués destinés au traitement de troubles médicaux
WO2017035408A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035351A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles médicaux
WO2017035355A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés éther pour le traitement de troubles médicaux
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035409A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles immunitaires et inflammatoires
WO2018005552A1 (fr) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
IL303696B1 (en) 2017-03-01 2024-10-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
JP7307723B2 (ja) 2017-10-18 2023-07-12 ジュビラント エピパッド エルエルシー Ｐａｄ阻害剤としてのイミダゾ－ピリジン化合物
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PL3704120T3 (pl) 2017-11-24 2024-09-16 Jubilant Episcribe Llc Związki heterocykliczne jako inhibitory prmt5
AU2019234185B2 (en) 2018-03-13 2024-08-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
WO2020051532A2 (fr) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Composés macrocycliques pour le traitement de troubles médicaux
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
WO2023164238A1 (fr) * 2022-02-25 2023-08-31 Regents Of The University Of Minnesota Inhibiteurs de protéase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215297A2 (fr) * 1985-08-14 1987-03-25 G.D. Searle & Co. Amides dipeptides substitués
EP0288965A2 (fr) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides inhibant l'activité de phospholipase-A2
EP0337774A2 (fr) * 1988-04-12 1989-10-18 Biomeasure, Inc. Antagonistes de CCK
EP0405506A1 (fr) * 1989-06-30 1991-01-02 Abbott Laboratories Ligants tétrapeptidiques du type B CCK récepteur
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
WO1991012264A1 (fr) * 1990-02-09 1991-08-22 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215297A2 (fr) * 1985-08-14 1987-03-25 G.D. Searle & Co. Amides dipeptides substitués
EP0288965A2 (fr) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides inhibant l'activité de phospholipase-A2
EP0337774A2 (fr) * 1988-04-12 1989-10-18 Biomeasure, Inc. Antagonistes de CCK
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
EP0405506A1 (fr) * 1989-06-30 1991-01-02 Abbott Laboratories Ligants tétrapeptidiques du type B CCK récepteur
WO1991012264A1 (fr) * 1990-02-09 1991-08-22 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.A.SMITH ET AL 'PEPTIDES,CHEMISTRY AND BIOLOGY; Proceedings 12th American Peptide Symposium, June 16-21, 1991,Cambridge,U.S.A.' 1992 , ESCOM , LEIDEN A.M.NADZAN; "Design of cholecystokinin analogs with high affinity and selectivity for brain CCK receptors" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922428A (zh) * 2015-06-25 2018-04-17 普洛麦格公司 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途
CN107922428B (zh) * 2015-06-25 2021-02-05 普洛麦格公司 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途

Also Published As

Publication number Publication date
GB9206757D0 (en) 1992-05-13
WO1993020099A2 (fr) 1993-10-14
AU3764593A (en) 1993-11-08

Similar Documents

Publication Publication Date Title
WO1993020099A3 (fr) Ligands pour les recepteurs de la cck et/ou la gastrine
EP0703785B8 (fr) Procedes de traitement de maladies et de troubles musculaires
HUP9600596A2 (en) Process for producing pharmaceutical compositions containing rapamycin, for treating cardiac inflammatory disease
CA2204616A1 (fr) Antagonistes de ppar gamma pour le traitement de l'obesite
RU93005168A (ru) Индолиновые производные, способ их получения, промежуточные соединения синтеза, использование промежуточных соединений и фармацевтическая композиция
EP0403158A3 (fr) Acides imidazolyl-alcénoiques
CA2274093A1 (fr) Composes substitues a base de pyrimidone et de pyridone et procedes d'utilisation
WO1997020823A3 (fr) Antagonistes de recepteurs
EP0201188A3 (fr) Pyrazolo[4,3-d]pyrimidine-7-ones substituées en 5, leur procédé de préparation et compositions pharmaceutiques les contenant
HUP9900773A3 (en) Use of carbazole derivatives for producing pharmaceutical compositions suitable for the treatment of congestive heart failure
HUT71548A (en) Tricyclic benzazepine and benzazocine derivatives, pharmaceutical compositions of vasopressin antagonistic activity containing them and process for preparing said compounds
HUT50445A (en) Process for producing pharmaceutical compositions suitable for preventing sexual diseases
CA2129995A1 (fr) Derives thiacycliques de piperidinyle
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
IL117824A (en) Pharmaceutical compositions containing 2-aryl-imidazol¬1,2-a¾pyridine-3-acetamide derivatives for treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia
MY129173A (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor
DE69628360T2 (de) Azepinonverbindungen zur Anwendung bei der Hemmung von ACE und NEP
CA2143610A1 (fr) Utilisation de norastemizole pour le traitement de troubles allergiques
CA2015515A1 (fr) Composes pharmaceutiques contenant des complexes antigene-anticorps et leur utilisation
IT1276167B1 (it) Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
ATE45949T1 (de) 4-alkoxy-pyrido(2,3-d>pyrimidin-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel.
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
CA2078869A1 (fr) Compositions pharmaceutiques contenant de l'ipriflavone, leur procede de preparation et leur emploi therapeutique relatif
WO2003045942A3 (fr) Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: BY*,UZ*

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Free format text: BY*,UZ*

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA